EGFR and head and neck squamous cell carcinoma: In case of risk factors/co-morbidities, HNSCC patients receive surgery plus radiochemotherapy, while patients presenting with a more advanced stage but still localized disease receive radiochemotherapy or radiotherapy plus modern targeted drugs such as Cetuximab, an inhibitory antibody for the epidermal growth factor receptor (EGFR), as curative approach [7–12].